SANWA KAGAKU KENKYUSHO Co., Ltd. (Head Office: Nagoya, President and CEO : Shusaku Isono, Suzuken Group, ; “SANWA KAGAKU”) has received Marketing…
—
Source: Kissei

Upacicalcet, a novel intravenous small molecule calcimimetic in late-stage development in Japan, may help control intact parathyroid hormone (iPTH) levels in patients with secondary hyperparathyroidism (SHPT)…
—
Source: Renal & Urology News

Calcimimetics are widely used for the treatment of secondary hyperparathyroidism (SHPT) in chronic renal failure patients. However, there are some problems with calcimimetics treatment…
—
Source: American Society of Nephrology – Kidney Week 2020